BrightMEM™ Corneal Allograft

BrightMEM Anterior Keratoplasty (BMAK) Surgical Training Resources

BrightMEM Information

Set up a meeting with our team to discuss BrightMEM.

Click to access their calendars.

Jared Young, CCO

Joe Tauber, MD, CMO

The BrightMEM Corneal Allograft

BrightMEM is an innovative corneal allograft composed of Descemet’s Membrane that promotes corneal re-epithelialization and functions as a robust basement membrane with natural long-term durability – representing a new treatment for patients with impaired corneal healing.

Clinical Experience (121 Cases Reported by 17 Surgeons)

  • Approximately 86.8% of cases reported were fully healed within a median healing time of 28 days (IQR 28-48)

  • For patients with follow-up care after 12 months, 100% reported complete re-epithelization

  • More than half reported improved vision within a month – and vision reportedly continues to improve with time

  • A successful graft retention rate of 93%

  • Significant improvement in limbal cell growth demonstrated by an improved central staining grade from 3.2+ to 2.2+

  • Neovascularization drops from an average of 71.4% to just 5.8%

  • No infectious, inflammatory or rejection complications were reported

Ideal Patients

• Non-healing corneal epithelial defect

• Herpes Zoster epitheliopathy

• Partial limbal stem cell deficiency (≤75%) with or without epithelial defect

• Post-infectious / post-operative Neurotrophic keratitis

• Chronic epitheliopathy

• Medicamentosa / toxicity / CL overuse LSCD